Gaps, tensions, and conflicts in the FDA approval process: Implications for clinical practice

Journal of the American Board of Family Practice

Volumn 17, Issue 2, 2004, Pages 142-149

  Deyo, Richard A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; CISAPRIDE; DEXFENFLURAMINE; NEW DRUG;

ADVISORY COMMITTEE; CLINICAL PRACTICE; CONSULTATION; CONSUMER; COST BENEFIT ANALYSIS; DEVICE; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HEARTBURN; HUMAN; LIFE SATISFACTION; MEDICAL FEE; MEDICAL LITERATURE; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PHYSICIAN; PHYSICIAN ATTITUDE; POSTMARKETING SURVEILLANCE; PROCESS DEVELOPMENT; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; UNITED STATES; UNSPECIFIED SIDE EFFECT; ARTICLE; CONFLICT OF INTEREST; ETHICS; LEGAL ASPECT; METHODOLOGY; ORGANIZATION; SAFETY; STANDARD;

CONFLICT OF INTEREST; CONSULTANTS; DECISION MAKING, ORGANIZATIONAL; DEVICE APPROVAL; DRUG APPROVAL; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 3242880319     PISSN: 08938652     EISSN: 15448770     Source Type: Journal    
DOI: 10.3122/jabfm.17.2.142     Document Type: Review

References (29)

1. Lipsky MS, Sharp LK. From idea to market: the drug approval process. J Am Board Fam Pract 2001;14:362-7.
2. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
3. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999;281:1728-34.
4. Maisel WH, Sweeney MO, Stevenson WG, Ellison KE, Epstein LM. Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator devices. JAMA 2001;286:793-9.
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
6. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 68 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 2002;288:49-57.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
8. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
9. Moore TJ. Deadly medicine: why tens of thousands of heart patients died in America's worst drug disaster. New York: Simon and Schuster; 1995.
10. Petersen M. Diuretics' value drowned out by trumpeting of newer drugs. The New York Times 2002 Dec 18;Sect A:32.
11. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947-57.
12. Gahart MT, Duhamel LM, Dievler A, Price R. Examining the FDA's oversight of direct-to-consumer advertising. Health Aff (Millwood) 2003 Suppl W3-120-3.
13. Ramsey SD, Luce BR, Deyo R, Franklin G. The limited state of technology assessment for medical devices: facing the issues. Am J Manag Care 1998;4 Spec No:SP188-99.
14. Merrill RA. Modernizing the FDA: an incremental revolution. Health Aff (Millwood) 1999;18:96-111.
15. Milestones in US food and drug law history. United States Food and Drug Administration.http://www.fda.gov/opacom/backgrounders/miles.html, accessed 8/19/02.
16. Handelsman H. Intermittent positive pressure breathing (IPPB) therapy. Health Technol Assess Rep 1991;(1):1-9.
17. FDA Center for Devices and Radiological Health. Office of Device Evaluation annual report 2002. Available at: URL: http://www.fda.gov/cdrh/annual/fy2002/ode/index.html.
18. Willman D. How a new policy led to seven deadly drugs. The Los Angeles Times 2000 Dec 20;Sect. A:1.
19. Adams C, Hensley S. Health and Technology: drug makers want FDA to move quicker. Wall Street Journal 2002 Jan 29;Sect. B:12.
20. Adams C. FDA may start assessing fees on makers of medical devices. The Wall Street Journal 2002 May 21;Sect. D:6.
21. Angell M, Relman AS. Prescription for profit. The Washington Post 2001 Jun 20;Sect. A:27.
22. Adams C. FDA searches for an elixir for agency's attrition rate. The Wall Street Journal 2002 Aug 19;Sect. A:4.
23. Goldberg R. FDA needs a dose of reform. The Wall Street Journal 2002 Sep 30;Sect. A:16. Available at: URL: http://www.aei.brookings.org/policy/page.php?id=113
24. Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. JAMA 1998;279:1571-3.
25. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration: your report can make a difference. J Gen Intern Med 2003;18:57-60.
26. Wood AJJ. The safety of new medicines: the importance of asking the right questions. JAMA 1999;281:1753-54.
27. Cauchon D. FDA advisers tied to industry. USA Today 2000 Sep 25;Sect. A:1.
28. Cauchon, D. Number of drug experts available is limited. Many waivers granted for those who have conflicts of interest. USA Today 2000 Sep 25;Sect. A:10.
29. Gribbin A. House investigates panels involved with drug safety. Mismanagement claims spur action. The Washington Times 2001 Jun 18;Sect. A:1.